The trajectory of companies tied to the drug's history presents a intricate investment landscape. While the initial success generated substantial profits , generic alternatives have significantly impacted revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of patent safeguards, evolving medical trends , and